Topology

Scientific Discovery AI Map

Updated
103
Map entries
9
Research areas
6
Clinical programs tracked
3
Tracked at Phase 3 / filing
MModel
VVertically Integrated
Foundation models (top) power application domains (middle), supported by infrastructure (bottom). Columns show funding stage: Non-Commercial (academic/open-source), Early Stage (pre-seed → Series A), Late Stage (Series B+, public, pharma). Hover any chip for details.
Category
Non-Commercial
Early Stage
Late Stage
Foundation Models
Protein & Molecular
OpenFold3Open sourceOSSM
Boltz-2MITOSSM
EvolutionaryScaleBiohub / ESMM
Baker LabUW/IPDNOBELV
Boltz$28M seedM
Basecamp Research$140M Series CM
Chai Discovery$400M Series C$3.8B VALM
Isomorphic Labs$2.1B Series BV
AlphaFoldDeepMindNOBELM
Cradle$100M+M
Genomic & Cellular
Arc StateVirtual cellM
Evo 2Arc InstituteOSSM
Chemistry & Synthesis
AiZynthFinderAstraZenecaOSSM
Ex
Excelsior$95M
Materials
MACECambridgeOSSM
M3GNet / CHGNetUCSD / BerkeleyOSSM
NequIP / AllegroHarvardOSSM
GNoMEDeepMindM
MatterGenMicrosoftOSSM
MatterSimMicrosoftOSSM
Application Domains
Small Molecule Drug Discovery
PostEraProtonPFIZER
Terray$226M
Insitro$743M
Nimbus / TakedaZasocitinib
IambicNASDAQ: IAMV
InsilicoHKEX: 3696V
RLAYRelay
RXRXRecursion
RocheInavolisib
Antibody, Biologics & Gene Therapy
Dyno Tx$109M
Retro Bio$1BSMALL MOL.
Materials
MA
MARSShenzhen
Prometheus$12B Series BBEZOS
SES AI$16M rev
Mitra ChemGMSAMPLES
Infrastructure
Autonomous Labs & AI Scientists
OpenAIGPT-Rosalind
InsilicoLife Star
AlphaEvolveDeepMind
Owkin$332M
Picks & Shovels
Asimov$209M
Opentrons$1.8B val
SandboxAQ$5.75B val
TWST$377M rev
TEM$1.27B rev
CERT$419M rev
AnthropicClaude Science
TMO$44.6B rev
NVIDIABioNeMo
Benchling$6.1B val
GinkgoNYSE: DNA
Illumina$4.3B rev
DNAnexus$473M+
Dotmatics$5.1B acq
Field Maturity

Qualitative editorial assessments, not measured percentages of a field being solved. Select a field for evidence and sources.

Selected Clinical Programs

AI-designed, AI-engineered, and computationally enabled programs. Stages refer to the cited indication; trial progress and regulatory review are not approval. Select a drug for its source.

NDA review
ZasocitinibNimbus / Takeda
Small mol.Plaque psoriasis (TYK2)
Phase 3
GB-0895Generate Bio
AntibodyAsthma (anti-TSLP)
Phase 3
RentosertibInsilico
Small mol.Lung fibrosis (TNIK)
Phase 1/2a
ABS-201Absci
AntibodyHair loss (anti-PRLR)
Phase 1/2
REC-1245Recursion
Mol. glueSolid tumors (RBM39)
Phase 1/1b
IAM1363Iambic
Small mol.HER2-altered cancers
Topology Research · Updated November 2, 2026Feedback? DMs open on XNot investment advice